Dermatomyositis | A Drug Pipeline Analysis Report 2018 | Technavio

LONDON--(BUSINESS WIRE)-- Technavio has announced their latest analysis report on the drug pipeline for dermatomyositis. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat dermatomyositis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180813005244/en/

Technavio has published a new report on the drug development pipeline for dermatomyositis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Dermatomyositis: Market overview

Dermatomyositis is an inflammatory disease of the muscles and skin marked by muscle weakness and severe skin lesions. It is an auto-immune disease, and the cause of the disease is unknown. It is mainly developed when an attack on muscle tissue occurs by white blood cells called T cells and B cells, which are produced by the immune system to fight infection.

According to a senior market research analyst at Technavio, “As per the data published by the Committee for Orphan Medical Products in November 2014, dermatomyositis affected approximately 1.7 in 10,000 people in the EU.”

Dermatomyositis: Segmentation analysis

This pipeline analysis report segments the dermatomyositis market based on therapies employed (monotherapy and combination therapy), RoA (oral, subcutaneous, and intravenous), therapeutic modality (small molecule, monoclonal antibody, antibody, fusion protein, vaccine, and oligonucleotide), targets (cells for immune system and others), MoA (immunostimulant and others), geographical segmentation (US, Hungary, France, Czech Republic, Germany, Italy, and Japan), and recruitment status (active, not recruiting, completed, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, more than 36% of the molecules that are being investigated for the treatment of dermatomyositis are small molecules. These small molecules are chemically manufactured active substances that can enter cells easily.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

• Drugs under development
• Indications coverage

Drug Development Strategies

• Therapies employed
• RoA
• Therapeutic modality
• Geographical coverage

Recruitment Strategies

• Recruitment status
• Gender
• Age

Key Companies

• Type of players
• Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180813005244/en/